Lantern Pharma to Present AI-Driven Oncology Pipeline at ThinkEquity Conference

Lantern Pharma (NASDAQ: LTRN), an artificial intelligence company focused on developing cancer therapies, announced that its management team will present at the ThinkEquity Conference on Thursday, October 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York. The presentation comes at a critical time for the company as it advances its AI-driven oncology pipeline through clinical development stages.

The company's proprietary AI and machine learning platform, RADR®, represents a significant advancement in drug discovery methodology. The platform leverages over 200 billion oncology-focused data points and utilizes more than 200 advanced machine learning algorithms to address complex challenges in oncology drug development. This technological approach aims to transform the traditional cost structure and timeline associated with bringing new cancer treatments to market.

Lantern Pharma's growing pipeline includes therapies spanning multiple cancer indications, covering both solid tumors and blood cancers, along with an antibody-drug conjugate program. The company currently has a Phase 2 clinical program and multiple Phase 1 clinical trials underway. The full scope of the company's development programs and platform capabilities can be reviewed in their official announcements available at https://ibn.fm/QSF41.

The significance of Lantern Pharma's approach lies in its potential to address the substantial financial and temporal challenges facing oncology drug development. Traditional cancer drug development can take over a decade and cost billions of dollars, whereas AI-driven approaches like Lantern's aim to significantly reduce both time and cost while improving success rates. The company estimates its pipeline of innovative product candidates has a combined annual market potential exceeding $15 billion USD.

Beyond financial implications, the company's technology holds promise for addressing critical unmet medical needs in oncology. By accelerating the identification and development of effective cancer treatments, Lantern Pharma's approach could potentially provide life-changing therapies to hundreds of thousands of cancer patients worldwide. The company maintains ongoing updates and news regarding its progress through its corporate communications channel at https://ibn.fm/LTRN.

The presentation at the ThinkEquity Conference provides investors and industry observers with insight into how artificial intelligence is reshaping pharmaceutical development, particularly in the high-stakes field of oncology. As healthcare costs continue to rise and patients await new treatment options, technologies that can streamline drug discovery while maintaining scientific rigor represent an important evolution in medical research methodology.